Sign Out
Anaphylaxis and severe hypersensitivity reactions are possible as with any intravenous protein product. Should such reactions occur, treatment with the product should be discontinued and appropriate treatment should be administered.
Development of activity-neutralizing antibodies has been detected in patients receiving factor VIII-containing products. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, an assay that measures factor VIII inhibitor concentration should be performed.
